it works in vivo, it triggers ferroptosis....and it's unreadable, especially because they threw one or two acronyms in the paper...
I understood nothing! Except that it ... - Advanced Prostate...
I understood nothing! Except that it sounds good: mesoporous superparamagnetic iron oxide nanoparticle for tumor ferroptosis therapy
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
9 Replies
•
In layman's terms it's called.....Supercalifragilisticexpialidocious! 😀
My take is: They have a molecule that can be made very magnetic by an external magnetic field. Most likely the molecule can be attached to something like the PSMA ligand used in Pluvicto. They can inject the liganded nano-particles, which will then glom onto cells exhibiting PSMA (or some other protein). When the particles are either attached to an appropriate cell, or have been cleared from the body, they can set up an oscillating magnetic field where they choose. The oscillating magnetic field will magnetize the particles and 'shake' them. The shaking is likely to disrupt the cells causing apoptosis.
It would be unlike radioactive liganded particles because there would be no activity until the magnetic field is applied. Since radioactive particles emit particles all the time, many of them will pop off while they are circulating and haven't reached their destination.
John
Yes they were studying something similar, which would be great: repeatable and with no radiations. But here they talk also about ferroptosis.
When the ROS level is over a threshold ferroptosis is introduced, by using SPION loaded with Sorafenib and another component against triple negative breast cancer cells they achieve 88 % cell deaths. The toxicity seems low, should be repetable. 4T1 cells are the hardest to treat!
Closer to a cure? 😅
I have tried with chatgpt, here is the result:
The abstract outlines the development of mesoporous superparamagnetic iron oxide nanoparticles (MSPIONs) to address limitations in existing drug delivery systems (DDS) for cancer treatment. Traditional mesoporous organosilica nanoparticles (MON) degrade slowly in vivo and their components don't support cell nutrition or cancer theranostics. Meanwhile, superparamagnetic iron oxide nanoparticles (SPION), though effective in MRI and fast degrading in tumor environments, lack mesoporosity, which limits their drug loading capacity.
To overcome these, MSPIONs were engineered with an average diameter of 70 nm and pores of 3.9 nm. Drugs sorafenib (SFN) and brequinar (BQR) were successfully loaded into these MSPIONs, yielding high drug loading contents. These loaded MSPIONs utilize the generated iron ions for ferroptosis—a form of iron-dependent cell death—through various biochemical interactions in the tumor microenvironment. This results in enhanced tumor cell death, making MSPIONs a promising approach for ferroptosis-based cancer therapy.
This breakthrough combines the benefits of rapid biodegradability and high drug loading efficiency in a mesoporous structure, aiming for effective cancer treatment with potential for high clinical translation due to its simple production process and significant efficacy as demonstrated in tumor-bearing mice.
When asked if it is an important discovery/technology:
The development of mesoporous superparamagnetic iron oxide nanoparticles (MSPIONs) for use in cancer therapy is quite significant for several reasons:
Enhanced Drug Delivery: MSPIONs address a critical challenge in nanoparticle-based drug delivery systems—the low drug loading capacity of traditional superparamagnetic iron oxide nanoparticles (SPIONs). By incorporating a mesoporous structure, these nanoparticles can carry larger quantities of therapeutic agents, which can enhance treatment efficacy.
Improved Imaging and Therapy Integration: The superparamagnetic properties of MSPIONs make them useful as MRI contrast agents, providing a dual function: diagnostic imaging and therapeutic agent delivery. This integration can facilitate more targeted treatments, allowing for real-time monitoring of therapeutic delivery and response.
Promotion of Ferroptosis: The ability of these nanoparticles to induce ferroptosis—a form of programmed cell death distinct from apoptosis—is particularly valuable. Ferroptosis is triggered by iron-dependent oxidative stress within cells, which is lethal to cancer cells. This provides a new avenue for cancer treatment, particularly for types of cancer that are resistant to conventional therapies.
Biocompatibility and Safety: The design of MSPIONs includes features that potentially enhance their biocompatibility and safety profile, such as a simple production process and the absence of harsh chemicals or surfactants. This aspect is crucial for clinical translation and patient safety.
Potential for Clinical Translation: The simplicity of the synthesis process for MSPIONs and their scalable nature make them promising candidates for widespread clinical use. The ability to produce them without complex or costly materials or methods means they could be more easily adopted in diverse healthcare settings.
